Mobia Medical initiated full-year 2026 revenue guidance of $54 million to $56 million, representing 69% to 75% growth over the prior year. The company reported second-quarter revenue of $13.5 million, a 102% increase year-over-year, with a gross margin of 83.2%. Selling, general and administrative expenses were $26.9 million, and the net loss was $21.0 million, or $1.10 per share. Cash and cash equivalents stood at $177.1 million as of June 30, 2026, following the May initial public offering that raised $134 million in net proceeds. Management expects gross margin to remain in the low 80s and highlighted reimbursement stability through a Category 1 CPT code and New Tech APC 1580 with Medicare reimbursement of approximately $45,000.
Mobia Medical, Inc. Common StockCompany issues strong 2026 revenue guidance and reports robust Q2 growth, indicating positive financial outlook.
ARKO Petroleum Corp.